Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Oral Edaravone in Healthy Adult Subjects
NCT05342597Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edaravone in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero up to Infinity, Maximum Plasma Concentration and 10 more. Started Jun 2019; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05342597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05342597.